Comparative Pharmacology
Head-to-head clinical analysis: FLOMAX versus TAMSULOSIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOMAX versus TAMSULOSIN HYDROCHLORIDE.
FLOMAX vs TAMSULOSIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective antagonist of alpha-1A and alpha-1D adrenergic receptors in the prostate, bladder base, and bladder neck, leading to relaxation of smooth muscle and improved urinary flow.
Selective antagonist of alpha-1A and alpha-1D adrenergic receptors in the prostate, bladder neck, and prostatic urethra, causing smooth muscle relaxation and improved urine flow.
0.4 mg orally once daily, approximately 30 minutes after the same meal each day. If no response after 2-4 weeks, may increase to 0.8 mg once daily.
0.4 mg orally once daily, approximately 30 minutes after the same meal each day. For patients who fail to respond to 0.4 mg after 2-4 weeks, dose may be increased to 0.8 mg once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 14-15 hours (range 6-20 hours) in healthy adults, allowing once-daily dosing.
9-13 hours in healthy subjects, but can increase to 14-16 hours in elderly patients. This supports once-daily dosing, though steady-state is reached by day 5.
Primarily hepatic metabolism (CYP3A4, CYP2D6) with <10% excreted unchanged in urine; fecal excretion accounts for ~76% of metabolites.
Primarily hepatic metabolism (CYP3A4 and CYP2D6) followed by renal excretion. Approximately 75-90% of a dose is excreted in urine as inactive metabolites, with <10% as unchanged drug. Fecal excretion accounts for 10-15%.
Category C
Category A/B
Alpha-1 Blocker
Alpha-1 Blocker